Palisade Bio Inc (PALI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $201.01M
Last updated: Nov 17, 2026 at 11:06 AM ET
Palisade Bio Inc (PALI) Stock Forecast
Analysts expect Palisade Bio (PALI) to earn -$0.24 per share in the fiscal year ending Dec 31, 2026, on revenue of $500000. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.70, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 30.0% |
| Buy | 7 | 70.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.24
- EPS consensus, revenue $500000
- Fiscal year ending Dec 31, 2027
- -$0.31
- EPS consensus
- Next report
- Mar 18, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.24 to -$0.24 | 4 | $500000 | $500000 to $500000 | 8 |
| Dec 31, 2027 | -$0.31 | -$0.40 to -$0.22 | 8 | N/A | N/A | 8 |
Quarterly Estimates
The EPS consensus is -$0.07 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.10 to -$0.05 | 12 |
| Mar 31, 2027 | -$0.07 | -$0.08 to -$0.05 | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 11 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 5 |
| Fiscal year ending Dec 31, 2027 | 1 | 5 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.23.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.24 | -$0.22 | -$0.22 | -$0.23 | -$0.23 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.31 | -$0.28 | -$0.28 | -$0.28 | -$0.28 | N/A |
| Quarter ending Mar 31, 2027 | -$0.07 | -$0.07 | -$0.07 | -$0.07 | -$0.07 | N/A |
Frequently Asked Questions About PALI
What is the PALI stock forecast?
Consensus analyst estimates put Palisade Bio's EPS at -$0.24 for the fiscal year ending Dec 31, 2026, on revenue of $500000. The consensus rating from 10 analysts is Buy.
How do analysts rate PALI stock?
Of 10 analysts covering Palisade Bio, 3 rate it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PALI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.24, with estimates from -$0.24 to -$0.24 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.31, with estimates from -$0.40 to -$0.22 from 8 analysts.
What revenue do analysts expect from Palisade Bio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $500000, with estimates from $500000 to $500000.
How many analysts cover PALI?
10 analysts rate Palisade Bio stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PALI pages: Overview, Earnings, Forecast, Financials, Competitors